

Mark Voskoboynik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4426966/publications.pdf>

Version: 2024-02-01

22
papers

215
citations

1040056

9
h-index

1058476

14
g-index

22
all docs

22
docs citations

22
times ranked

479
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabemlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, 434-434.	1.6	2
2	ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).. Journal of Clinical Oncology, 2022, 40, TPS205-TPS205.	1.6	1
3	Cardiovascular disease and malignant melanoma. Melanoma Research, 2022, Publish Ahead of Print, .	1.2	3
4	Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1). Cancer Research, 2022, 82, CT041-CT041.	0.9	1
5	Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1).. Journal of Clinical Oncology, 2022, 40, 2560-2560.	1.6	1
6	Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC. Clinical Lung Cancer, 2021, 22, e425-e430.	2.6	15
7	Standard-Dose Osimertinib in EGFR-Mutated Nonâ€“Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease. JCO Precision Oncology, 2021, 5, 561-568.	3.0	1
8	Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabemlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.. Journal of Clinical Oncology, 2021, 39, 2579-2579.	1.6	4
9	Improving regional access: Phase 1 teletrials in the era of COVIDâ€™19. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 416-417.	1.1	0
10	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2021, 19, 434-446.	1.9	16
11	Firstâ€™inâ€™human phase 1 study of MKâ€™1248, an antiâ€™glucocorticoidâ€™induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors. Cancer, 2020, 126, 4926-4935.	4.1	46
12	Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, 150-156.	0.8	11
13	<p>A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia</p>. Drug Design, Development and Therapy, 2020, Volume 14, 1177-1189.	4.3	21
14	Setting the Stage. Chest, 2019, 156, 633-634.	0.8	0
15	Prospective analysis of 895 patients on a UK Genomics Review Board. ESMO Open, 2019, 4, e000469.	4.5	22
16	An update on adjuvant systemic therapies in melanoma. Melanoma Management, 2019, 6, MMT28.	0.5	10
17	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. British Journal of Cancer, 2017, 117, 938-946.	6.4	18
18	Clinicopathological characteristics associated with <sc>BRAF</sc>^{K601E} and <sc>BRAF</sc>^{L597} mutations in melanoma. Pigment Cell and Melanoma Research, 2016, 29, 222-228.	3.3	16

#	ARTICLE	IF	CITATIONS
19	Immunotherapy for bladder cancer: rediscovering an old friend. <i>BJU International</i> , 2016, 117, 721-724.	2.5	0
20	“Charting a new course for prostate cancer” currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1253-1256.	2.4	7
21	Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. <i>Biochemistry Research International</i> , 2014, 2014, 1-9.	3.3	18
22	Early Cardiovascular Death in Patients with Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1572-1573.	27.0	2